Plasma osteopontin is an early detection and prognostic marker in malignant pleural mesothelioma NYU Cancer Institute’s Harvey Pass, M.D., professor of cardiothoracic surgery and surgery; division chief of thoracic surgery and thoracic oncology, at NYU Langone Medical Center

Scientists have established a mouse model for human malignant mesothelioma (MM) that will provide valuable insight into cancer development and progression along with new directions for design of therapeutic strategies.

Current predictions of the future incidence of asbestos-related disease have been substantially underestimated, according to new modelling to be presented in Melbourne today by an epidemiologist from The Australian National University.